Stock analysis posts tagged "johnson and johnson" from Openbook.
Smith & Nephew's talks to merge with J&J's DePuy Synthes unit collapsed over who would be chief executive, ending a deal valuing the business at up to $22bn.
J&J beat on adjusted EPS and raised full-year guidance, yet the shares closed 5.73% lower at $248.61. MedTech growth of just 2.5% is the reason.